SmartMatch Study for Rare Gynecologic Cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new approach called SmartMatch that looks at the unique traits of your tumor to find the best treatment for you. The goal is to see if this personalized approach is feasible and helpful for people with rare gynecologic cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a rare gynecologic cancer that has spread, cannot be removed by surgery, or needs more treatment.
- You have a recent tumor sample (from surgery or biopsy) that can be tested.
- You are generally well enough to receive cancer treatment (performance status 0-2).
- You agree to let the study team review your medical records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
This study collects evidence on personalized (“targeted”) cancer treatments for adults with rare cancers or rare tumor changes. If you may qualify, it may help make these treatments more widely available in the future by studying how well they work and how patients feel.
This study is watching and collecting data from patients with rare gynecologic tumors. It uses special tests on your tumor samples to learn more about these cancers, which may help find better treatments in the future.
This trial is collecting tissue and blood samples from people with rare gynecological cancers, such as unusual ovarian tumors, uterine sarcomas, or vulvar cancer. The goal is to use advanced lab tests (called multi-omics) to learn more about these cancers and improve treatment.
This study is looking at people with rare cancers affecting the female reproductive system. It may help researchers learn more about how these cancers behave and how best to follow patients over time.
This trial tests whether using a personalized approach (matching your tumor's genetic profile to a targeted drug) can help people with advanced solid cancers live longer. It is for people whose cancer is not responding to standard treatments and who have a genetic change that can be targeted by an FDA-approved drug not usually used for their cancer type.
Hear when a new Malignant Female Reproductive System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.